Cancer Genomics and Proteomics

About Cancer Genomics and Proteomics

About Cancer Genomics and Proteomics

Cancer Genomics and Proteomics is a peer-reviewed scholarly journal published by International Institute of Anticancer Research (Greece). It focuses on Q2. Publication coverage spans 2004-2026.

Key indicators: ISSN 1790-6245, 1109-6535; H-index 53.

Understanding This Journal's Metrics

Journal metrics help researchers assess fit, but they must be interpreted in context:

• H-index (53): Strong citation impact — 53 articles cited at least 53 times each, reflecting solid influence.

Publishing in Cancer Genomics and Proteomics

An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.

• Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
• Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.

Is This Journal Right for Your Paper?

• Audience match: Will the journal's readers cite and build on your findings?
• Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
• Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
• Open access needs: Check funder mandates and whether the journal offers compliant OA options.

Frequently Asked Questions

What is the ISSN of Cancer Genomics and Proteomics?
1790-6245, 1109-6535.

Who publishes Cancer Genomics and Proteomics?
International Institute of Anticancer Research.

What are Cancer Genomics and Proteomics's metrics?
H-index 53.

Is Cancer Genomics and Proteomics peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.